Document is current
Any future updates will be listed below
-
Authors
Sobhy, Mohamed
Abdelhamid, Magdy
El Etriby, Adel Mohamed
Gamaleldin, Mohamed Fathy Soliman
Youssef, Ahmed Mohamed Helmy
Khalife, Natasha
Ragy, Hany
Reda, Ashraf
Sobhy, Maichel
Nawar, Mostafa
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 19 August 2024
Accepted: 10 February 2025
First Online: 21 March 2025
Declarations
:
: Magdy Abdelhamid received speaker honoraria from Pfizer, Novartis, and AstraZeneca, is an advisory board member with Bayer, and received research grants or other funding from Pfizer. Mohamed Sobhy, Adel Mohamed El Etriby, Hany Ragy, Ashraf Reda, Maichel Sobhy, and Mostafa Nawar have no conflicts to disclose. Natasha Khalife is an employee of IQVIA, which conducted the study on behalf of the sponsor. Mohamed Fathy Soliman Gamaleldin and Ahmed Mohamed Helmy Youssef are employees of Pfizer Inc., the study sponsor.
: The study protocol (available upon request) was submitted and approved by the Alexandria University Hospital (MOH) Ethics Committee and the Institutional Review Board of each participating hospital (Table S4, Supplementary Material). The registry was conducted in accordance with the principles of the Declaration of Helsinki, local regulatory requirements, and the International Conference on Harmonisation Good Pharmacoepidemiological and Clinical Practice guidelines []. All study participants provided written informed consent, and the confidentiality and anonymity of all enrolled patients were maintained.
